Articles by James Calloway
Coca-Cola to Discontinue Frozen Products Ahead of Q4 Earnings Report
Coca-Cola will phase out its frozen product lines in North America by early 2026, as shares edge higher ahead of Tuesday's quarterly results. Options markets anticipate a 3% post-earnings move.
Cisco Gains Ahead of Earnings Amid Tech Sector Volatility
Cisco shares rose 3% to $84.82 Friday as investors positioned for quarterly results and key economic data next week. The company reports February 11 with analysts expecting $1.02 EPS on $15.12 billion revenue.
Netflix Gains as DOJ Expands Warner Deal Scrutiny; Hastings Files Share Transfer
Netflix shares closed 1.6% higher at $82.20 amid a deepening Justice Department antitrust review of its $82.7 billion Warner Bros Discovery acquisition. Director Reed Hastings reported transferring 241,944 shares via a family trust.
Healthcare Sector Sees Divergence: Molina Plunges on Outlook, XLV Gains Amid Regulatory Warnings
Molina Healthcare plummeted 25.5% after slashing its 2026 profit forecast and announcing a Medicare Part D exit, while the Health Care Select Sector SPDR Fund (XLV) rose 1.8%. Regulatory warnings on compounded obesity drugs added pressure to the sector.
Amazon Shares Drop 5.6% on $200 Billion AI Spending Forecast
Amazon stock declined sharply after projecting a major increase in capital expenditures for 2026, even as broader markets reached new highs. Investors are scrutinizing the returns from massive tech investments in artificial intelligence.
Home Depot Shares Edge Higher Ahead of Key Economic Data, Q4 Earnings
Home Depot stock gained 0.7% Friday as investors await delayed jobs and inflation reports. The home improvement retailer's Q4 earnings, due Feb. 24, will test demand in a cautious housing market.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.